Drugs / HTI-2088
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03203811 | Feb → Oct 2017 | diabetes mellitus | Hengrui Therapeutics, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HTI-2088 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03203811 ↗ |
| Route | Oral | “single oral doses of HTI-2088 tablets” NCT03203811 ↗ |